Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

(2019) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

(2018) David Ghez et al.   BLOOD

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

(2018) John M. Burke et al.   Clinical Lymphoma Myeloma & Leukemia

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

A multiprotein supercomplex controlling oncogenic signalling in lymphoma

(2018) James D. Phelan et al.   NATURE

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assembly mechanism of the CARMA1–BCL10–MALT1–TRAF6 signalosome

(2018) Liron David et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma

(2018) David J. Andorsky et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).

(2018) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation

(2018) Rashmi Kanagal-Shamanna et al.   CANCER

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition

(2017) Gabriele Varano et al.   NATURE

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia

(2017) Claudia Minici et al.   Nature Communications

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

(2017) Dan A. Landau et al.   Nature Communications

The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma

(2017) Jiyuan Zhang et al.   Cancer Discovery

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

(2017) Christian Grommes et al.   Cancer Discovery

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma

(2017) Georgios N. Pongas et al.   Oncotarget

Genomic characterization of primary central nervous system lymphoma

(2016) Kazutaka Fukumura et al.   ACTA NEUROPATHOLOGICA

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

(2016) P. M. Barr et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma

(2016) Keiichiro Hattori et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity

(2016) A. Ma ecka et al.   HAEMATOLOGICA

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

An improved smaller biotin ligase for BioID proximity labeling

(2016) Dae In Kim et al.   MOLECULAR BIOLOGY OF THE CELL

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma

(2016) Lixin Rui et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization

(2016) Chendi Zhan et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

(2016) F. Scherer et al.   Science Translational Medicine

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

(2016) Yanwen Jiang et al.   Cancer Discovery

Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity

(2016) A. Ma ecka et al.   HAEMATOLOGICA

MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma

(2015) Azahara Martinez-Lopez et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Targetable genetic features of primary testicular and primary central nervous system lymphomas

(2015) B. Chapuy et al.   BLOOD

Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas

(2015) E. Braggio et al.   CLINICAL CANCER RESEARCH

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies

(2015) David W. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy

(2015) Priscilla N. Kelly et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations

(2015) So Yamada et al.   LEUKEMIA & LYMPHOMA

Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus

(2015) Christopher M Tipton et al.   NATURE IMMUNOLOGY

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis

(2015) Jiyuan Zhang et al.   NATURE MEDICINE

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

(2015) Ana Ortega-Molina et al.   NATURE MEDICINE

Recurrent mutations ofCD79BandMYD88are the hallmark of primary central nervous system lymphomas

(2015) T. Nakamura et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

The B-cell antigen receptor integrates adaptive and innate immune signals

(2015) Kevin L. Otipoby et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens

(2015) Ryan M. Young et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

(2015) Scott A. Ezell et al.   Oncotarget

Mutational analysis of primary central nervous system lymphoma

(2015) Aurélie Bruno et al.   Oncotarget

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization

(2014) M. Avbelj et al.   BLOOD

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms

(2014) Jay A. Read et al.   Clinical Lymphoma Myeloma & Leukemia

Consequences of the recurrentMYD88L265Psomatic mutation for B cell tolerance

(2014) James Q. Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing

(2014) I Vater et al.   LEUKEMIA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

(2014) M. Ceribelli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity

(2014) Z. Sabouri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

(2014) Panagiotis Baliakas et al.   Lancet Haematology

Lymphoma risk in systemic lupus: effects of disease activity versus treatment

(2013) Sasha Bernatsky et al.   ANNALS OF THE RHEUMATIC DISEASES

How I treat CNS lymphomas

(2013) J. L. Rubenstein et al.   BLOOD

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

(2013) Wendy Béguelin et al.   CANCER CELL

SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas

(2013) Linfeng Chen et al.   CANCER CELL

Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma

(2013) U. Randen et al.   HAEMATOLOGICA

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

(2013) Marieta Caganova et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Basis of 9G4 B Cell Autoreactivity in Human Systemic Lupus Erythematosus

(2013) C. Richardson et al.   JOURNAL OF IMMUNOLOGY

Structural Architecture of the CARMA1/Bcl10/MALT1 Signalosome: Nucleation-Induced Filamentous Assembly

(2013) Qi Qiao et al.   MOLECULAR CELL

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Cis and Trans Regulatory Mechanisms Control AP2-Mediated B Cell Receptor Endocytosis via Select Tyrosine-Based Motifs

(2013) Kathleen Busman-Sahay et al.   PLoS One

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

(2013) M. Pfeifer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma

(2012) Elena Sebastián et al.   AMERICAN JOURNAL OF PATHOLOGY

Pathogenesis of Human B Cell Lymphomas

(2012) Arthur L. Shaffer et al.   Annual Review of Immunology

Germinal Centers

(2012) Gabriel D. Victora et al.   Annual Review of Immunology

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

(2012) Lomon So et al.   BIOCHEMICAL JOURNAL

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo

(2012) Lorena Fontan et al.   CANCER CELL

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL

(2012) Daniel Nagel et al.   CANCER CELL

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry

(2012) David Dominguez-Sola et al.   NATURE IMMUNOLOGY

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

(2011) Manuel Montesinos-Rongen et al.   ACTA NEUROPATHOLOGICA

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

(2011) A. Hadzidimitriou et al.   BLOOD

SYK inhibition and response prediction in diffuse large B-cell lymphoma

(2011) S. Cheng et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

(2011) T. L. Naylor et al.   CANCER RESEARCH

Selective Utilization of Toll-like Receptor and MyD88 Signaling in B Cells for Enhancement of the Antiviral Germinal Center Response

(2011) Baidong Hou et al.   IMMUNITY

Anergic Responses Characterize a Large Fraction of Human Autoreactive Naive B Cells Expressing Low Levels of Surface IgM

(2011) T. D. Quach et al.   JOURNAL OF IMMUNOLOGY

The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma

(2011) P Ruminy et al.   LEUKEMIA

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

(2010) M. Suljagic et al.   BLOOD

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

(2010) F. Marcucci et al.   BLOOD

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

(2010) C. C. Chu et al.   BLOOD

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

(2010) Yasemin Sancak et al.   CELL

Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter

(2010) Gabriel D. Victora et al.   CELL

Intrinsic Properties of immunoglobulin IgG1 Isotype-Switched B Cell Receptors Promote Microclustering and the Initiation of Signaling

(2010) Wanli Liu et al.   IMMUNITY

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins

(2010) V. Coelho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

(2010) C. J. Sneeringer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PI3K Isoforms p110  and p110  Are Essential for Pre-B Cell Receptor Signaling and B Cell Development

(2010) F. Ramadani et al.   Science Signaling

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

The Constant Region of the Membrane Immunoglobulin Mediates B Cell-Receptor Clustering and Signaling in Response to Membrane Antigens

(2009) Pavel Tolar et al.   IMMUNITY

Autoinhibition and adapter function of Syk

(2009) Yogesh Kulathu et al.   IMMUNOLOGICAL REVIEWS

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells

(2009) Uta Ferch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance

(2009) A. J. Gross et al.   JOURNAL OF IMMUNOLOGY

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Multiple layers of B cell memory with different effector functions

(2009) Ismail Dogan et al.   NATURE IMMUNOLOGY

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

(2009) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing

(2008) George R. Clemens et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

(2008) R. M. Young et al.   BLOOD

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

(2008) S Gobessi et al.   LEUKEMIA

Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay

(2008) Ola Söderberg et al.   METHODS

Unknown

(2008) Rosa Catera et al.   MOLECULAR MEDICINE

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Membrane recognition by phospholipid-binding domains

(2008) Mark A. Lemmon   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

The B Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B Cell Lymphomas

(2008) Yosef Refaeli et al.   PLOS BIOLOGY